Filing Details
- Accession Number:
- 0001787306-24-000161
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-26 16:21:01
- Reporting Period:
- 2024-11-22
- Accepted Time:
- 2024-11-26 16:21:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1787306 | Arcutis Biotherapeutics Inc. | ARQT | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1741987 | Patrick Burnett | C/O Arcutis Biotherapeutics, Inc. 3027 Townsgate Road Suite 300 Westlake Village CA 91361 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-11-22 | 16,023 | $0.00 | 144,692 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-11-22 | 16,023 | $10.14 | 128,669 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2024-11-22 | 16,023 | $0.00 | 16,023 | $3.64 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
218,500 | 2034-01-12 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $10.205 to $10.14, inclusive. The Reporting Person herebyundertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respectiveprice within the range set forth in this footnote.
- On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "VestingCommencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the ReportingPerson's continued service to the Issuer.